Atea Pharmaceuticals (AVIR) Research & Development (2019 - 2026)

Atea Pharmaceuticals' Research & Development history runs 8 years deep, the most recent figure standing at $41.1 million for Q1 2026.

• In Q1 2026, Research & Development rose 39.04% year-over-year to $41.1 million; the TTM figure through Mar 2026 stood at $159.6 million (up 37.43% YoY), while the FY2025 annual figure was $148.0 million, up 2.72% from the prior year.
• Research & Development was $41.1 million for Q1 2026 at Atea Pharmaceuticals, down from $47.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $57.6 million in Q1 2024 to a low of $4.9 million in Q3 2022.
• Historically, Research & Development has averaged $31.1 million across 5 years, with a median of $29.6 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Research & Development slumped 88.6% in 2022, then jumped 474.54% in 2023.
• A 5-year view of Research & Development shows it stood at $27.5 million in 2022, then climbed by 27.25% to $35.0 million in 2023, then retreated by 26.75% to $25.7 million in 2024, then jumped by 86.27% to $47.8 million in 2025, then dropped by 13.98% to $41.1 million in 2026.
• The last three Research & Development figures came in at $41.1 million (Q1 2026), $47.8 million (Q4 2025), and $38.3 million (Q3 2025), per Business Quant data.